Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation

The farnesoid X receptor (FXR) is involved in glucose and lipid metabolism regulation, which makes it an attractive target for the metabolic syndrome, dyslipidemia, atherosclerosis, and type 2 diabetes. In order to find novel FXR agonists, a structure-based pharmacophore model collection was develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuster, Daniela, Markt, Patrick, Grienke, Ulrike, Mihaly-Bison, Judit, Binder, Markus, Noha, Stefan M., Rollinger, Judith M., Stuppner, Hermann, Bochkov, Valery N., Wolber, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3254253/
https://www.ncbi.nlm.nih.gov/pubmed/22018919
http://dx.doi.org/10.1016/j.bmc.2011.09.056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3254253/
https://www.ncbi.nlm.nih.gov/pubmed/22018919
http://dx.doi.org/10.1016/j.bmc.2011.09.056

Ejemplares similares